Biotech executives almost never buy their own stock. Their compensation is heavily weighted toward equity grants, the dilution risk from secondaries is real, and clinical trial timing makes most insiders wary of the optics. So when several senior officers and board members at a small-cap biotech file Form 4 buys within days of each other, the signal cuts through the noise.
In the last 90 days we've flagged three small-cap biotechs where the cluster-buy pattern has lit up the Insider Score scoring system. All three have upcoming Phase II or Phase III readouts in the next nine months. All three have insiders adding meaningful personal stakes — not the token $5,000 director buys, but six-figure positions from C-suite executives.
We can't share the names here. But subscribers get them in their inbox the day the Insider Score crosses our internal threshold.
Key takeaways
- Cluster buying at small-cap biotech in last 90 days
- Upcoming Phase II / Phase III readouts within 9 months
- Six-figure insider stakes — not symbolic director buys
- Insider Score scoring system flagged all three above our threshold